Interventional firm Guidant of Indianapolis has entered into a purchase agreement to acquire everolimus-eluting stent technology from Biosensor of Singapore. The deal provides an exclusive worldwide license to Biosensor’s bioabsorbable polymer formulation technology in the field of everolimus-eluting stents, complementing Guidant’s exclusive license for the use of everolimus in the vascular system.
The agreement also provides a nonexclusive license to utilize the bioabsorbable polymer formulation technology with other drugs in drug-eluting stents controlled by Guidant. According to Biosensor, it retains exclusive rights to commercialize other drugs and drug-eluting stent-coating technologies that it has under development.
By AuntMinnie.com staff writers
March 20, 2003
Related Reading
Guidant launches Multi-Link Penta in Japan, March 12, 2003
Guidant acquires X Technologies, taps Mead to head vascular intervention, March 11, 2003
Guidant posts record 2002, January 30, 2003
Guidant/Cook deal in doubt, January 3, 2003
Guidant gets CE Mark for stent system, December 19, 2002
Copyright © 2003 AuntMinnie.com
